Back to Search
Start Over
Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial.
- Source :
-
Diabetes, obesity & metabolism [Diabetes Obes Metab] 2017 Jun; Vol. 19 (6), pp. 901-905. Date of Electronic Publication: 2017 Mar 02. - Publication Year :
- 2017
-
Abstract
- We assessed the effects of liraglutide treatment on five cardiovascular risk biomarkers, reflecting different pathophysiology: tumour necrosis factor (TNF)-α; soluble urokinase plasminogen activator receptor (suPAR); mid-regional pro-adrenomedullin (MR-proADM); mid-regional pro-atrial natriuretic peptide (MR-proANP); and copeptin, in people with type 2 diabetes with albuminuria. In a randomized, double-blind, placebo-controlled, crossover trial we enrolled people with type 2 diabetes and persistent albuminuria (urinary albumin-to-creatinine ratio [UACR] >30 mg/g) and estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m <superscript>2</superscript> . Participants received liraglutide (1.8 mg/d) and matched placebo for 12 weeks, in random order. The primary endpoint was change in albuminuria; this was a prespecified sub-study. A total of 32 participants were randomized, of whom 27 completed the study. TNF-α level was 12% (95% confidence interval [CI] 3; 20) lower after liraglutide treatment compared with placebo (P = .012); MR-proADM level was 4% (95% CI 0; 8) lower after liraglutide treatment compared with placebo (P = .038), and MR-proANP level was 13% (95% CI 4; 21) lower after liraglutide treatment compared with placebo (P = .006). In the present study, we showed anti-inflammatory effects of liraglutide treatment, reflected in reductions in levels of TNF-α and MR-proADM, while the reduction in MR-proANP levels may represent a clinically relevant benefit with regard to heart failure.<br /> (© 2017 John Wiley & Sons Ltd.)
- Subjects :
- Adrenomedullin blood
Adrenomedullin drug effects
Aged
Albuminuria drug therapy
Albuminuria etiology
Atrial Natriuretic Factor blood
Atrial Natriuretic Factor drug effects
Biomarkers blood
Cross-Over Studies
Diabetes Mellitus, Type 2 complications
Diabetes Mellitus, Type 2 drug therapy
Double-Blind Method
Female
Glycopeptides blood
Glycopeptides drug effects
Humans
Male
Middle Aged
Peptide Fragments blood
Peptide Fragments drug effects
Protein Precursors blood
Protein Precursors drug effects
Receptors, Urokinase Plasminogen Activator blood
Receptors, Urokinase Plasminogen Activator drug effects
Risk Factors
Tumor Necrosis Factor-alpha blood
Tumor Necrosis Factor-alpha drug effects
Albuminuria blood
Cardiovascular Diseases etiology
Diabetes Mellitus, Type 2 blood
Hypoglycemic Agents therapeutic use
Liraglutide therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1463-1326
- Volume :
- 19
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Diabetes, obesity & metabolism
- Publication Type :
- Academic Journal
- Accession number :
- 28105731
- Full Text :
- https://doi.org/10.1111/dom.12884